This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motzer, R. J. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 10.1200/JCO.2013.54.6911
Rights and permissions
About this article
Cite this article
Razzak, M. mTOR or VEGFR inhibition—get the order right. Nat Rev Urol 11, 488 (2014). https://doi.org/10.1038/nrurol.2014.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.198